An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy

Abstract

In the EAP, the safety profile of risdiplam was similar to what was reported in pivotal risdiplam clinical trials. These safety data provide further support for the use of risdiplam in the treatment of adult and pediatric patients with SMA.